← Leaderboards
Sumin Kang
Emory University
$9,704,133
Attributed
$10,021,952
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,021,952 · 7
By mechanism
R01$7,748,109 · 4
P01$1,246,778 · 1
T32$635,639 · 1
R21$391,426 · 1
Top collaborators
- Gregory B. Lesinski3 shared
Most similar at Emory University
Same institution · by research overlap
- Jason M Grayson$2,987,608
- Gina Nicole Alesi$112,021
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungCancer CellSignal TransductionMalignant NeoplasmsMediatingAttenuatedCellsIn VivoIn VitroPathway InteractionsResistanceCancer TherapyCancer TypeSignal PathwayPhosphorylationTranscription FactorTumorSeriesMetabolicLinkMolecularNeoplasm MetastasisProteinsNeoplastic Cell
Grant awards (29)
Dissecting and Targeting MAST1 Signaling in chemoresistant Cancers$434,313
R01 · FY2025 · CA · contact PI
Decoding and targeting saccharopine pathway in cancer metastasis$419,786
R01 · FY2025 · CA · contact PI
Graduate Program in Cancer Biology Training at Emory University$199,361
T32 · FY2025 · CA
Dissecting and Targeting MAST1 Signaling in chemoresistant Cancers$434,313
R01 · FY2024 · CA · contact PI
Project 1: Glutaminolytic GDH1 activation-dependent immunotherapy resistance in LKB1-mutant lung adenocarcinoma$399,749
P01 · FY2024 · CA · contact PI
Decoding and targeting saccharopine pathway in cancer metastasis$398,797
R01 · FY2024 · CA · contact PI
Graduate Program in Cancer Biology Training at Emory University$221,904
T32 · FY2024 · CA
Dissecting pemetrexed resistance in non-small cell lung carcinoma$208,517
R21 · FY2024 · CA · contact PI
Project 1: Glutaminolytic GDH1 activation-dependent immunotherapy resistance in LKB1-mutant lung adenocarcinoma$416,967
P01 · FY2023 · CA · contact PI
Decoding and targeting saccharopine pathway in cancer metastasis$411,390
R01 · FY2023 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$363,090
R01 · FY2023 · CA · contact PI
Graduate Program in Cancer Biology Training at Emory University$214,374
T32 · FY2023 · CA
Dissecting pemetrexed resistance in non-small cell lung carcinoma$182,909
R21 · FY2023 · CA · contact PI
Project 1: Glutaminolytic GDH1 activation-dependent immunotherapy resistance in LKB1-mutant lung adenocarcinoma$430,062
P01 · FY2022 · CA · contact PI
Decoding and targeting saccharopine pathway in cancer metastasis$419,786
R01 · FY2022 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$363,090
R01 · FY2022 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$370,500
R01 · FY2021 · CA · contact PI
Role of MAST1 kinase in cisplatin resistant cancers$356,850
R01 · FY2021 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$370,500
R01 · FY2020 · CA · contact PI
Role of MAST1 kinase in cisplatin resistant cancers$356,850
R01 · FY2020 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$370,500
R01 · FY2019 · CA · contact PI
Role of MAST1 kinase in cisplatin resistant cancers$346,144
R01 · FY2019 · CA · contact PI
Role of MAST1 kinase in cisplatin resistant cancers$356,850
R01 · FY2018 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$323,700
R01 · FY2018 · CA · contact PI
Role of MAST1 kinase in cisplatin resistant cancers$356,850
R01 · FY2017 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$323,700
R01 · FY2017 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$323,700
R01 · FY2016 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$323,700
R01 · FY2015 · CA · contact PI
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis$323,700
R01 · FY2014 · CA · contact PI